• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioCardia files 2nd FDA IDE bid for CardiAMP chronic myocardial ischemia, refractory angina study

January 5, 2018 By Fink Densford

BioCardia (NSDQ:BCDA) said today it filed for a second FDA investigational device exemption to launch a trial of its CardiAMP cell therapy for treating chronic myocardial ischemia and refractory angina as it seeks a second indication.

The San Carlos, Calif.-based company’s CardiAMP therapy uses autologous cells to treat chronic myocardial ischemia, and is designed to stimulate the body’s natural healing response.

“This therapeutic approach of focused implantation of the right combination of bone marrow-derived cells delivered intramyocardially for the treatment of refractory angina is supported by significant existing data. CardiAMP has pre-procedure selection criteria for patients that enhances the probability that patients receive the same effective dose of CD34+ cells that has shown efficacy in other large, recent trials,” chief medical officer Dr. Eric Duckers said in a prepared statement.

BioCardia said it is pursuing the indiciation after having already received FDA approvla for a Phase III trial of the CardiAMP in treating ischemic heart failure, which has already begun to enroll patients.

“The CardiAMP Chronic Myocardial Ischemia Trial is expected to benefit greatly from the experience and capabilities BioCardia has established in the CardiAMP Heart Failure Trial. Should the FDA approve the IDE and CMS grant a category B designation, as they have for the CardiAMP Heart Failure Trial, we anticipate that the first patients could be enrolled in the second half of 2018,” BioCardia CEO Peter Altman said in a press release.

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Regenerative Medicine Tagged With: BioCardia

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS